Treatment with SR18662 noticeably reduces development and proliferation of CRC cells. SR18662 exhibits enhanced efficacy in cutting down viability of multiple CRC mobile lines. Flow cytometry Investigation adhering to SR18662 remedy exhibits a rise in cells captured in possibly S or G2/M phases on the cell cycle and a significant boost in the amoun